Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of recently confirmed cases in Guinea, west Africa.

Original Source

Publication Date: 
22/12/2016
Ana Maria Henao-Restrepo, Anton Camacho, Ira M Longini & et al
Lancet
1-14
Attachment(s): 
Zaire Ebolavirus.pdf
Tags:
Ebola Virus Disease (Ebola Hemorrhagic Fever), Drugs, Vaccination, Guinea, Africa, Sierra Leone